Mainz Biomed B.V. (MYNZ)

NASDAQ: MYNZ · IEX Real-Time Price · USD
6.90
-0.09 (-1.22%)
At close: Sep 29, 2022 4:00 PM
6.89
-0.00 (-0.07%)
After-hours: Sep 30, 2022 4:49 PM EDT
-1.22%
Market Cap 99.86M
Revenue (ttm) 577,348
Net Income (ttm) -11.69M
Shares Out 14.48M
EPS (ttm) -1.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 11,085
Open 6.11
Previous Close 6.98
Day's Range 6.11 - 6.90
52-Week Range 6.06 - 30.00
Beta n/a
Analysts Buy
Price Target 25.50 (+269.8%)
Earnings Date n/a

About MYNZ

Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany. [Read more...]

Industry Diagnostics & Research
IPO Date Nov 5, 2021
Country Germany
Stock Exchange NASDAQ
Ticker Symbol MYNZ
Full Company Profile

Financial Performance

In 2021, MYNZ's revenue was $577,348, an increase of 16.98% compared to the previous year's $493,565. Losses were -$11.69 million, 1,891.9% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for MYNZ stock is "Buy." The 12-month stock price forecast is 25.5, which is an increase of 269.83% from the latest price.

Price Target
$25.5
(269.83% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Mainz Biomed Strengthens Board of Directors with Nomination of Dr. Heiner Dreismann and Gregory Tibbitts

Dr. Dreismann, Former Roche Molecular Diagnostics CEO, and Mr. Tibbitts, a Highly-accomplished Life-Sciences Executive, Provide Extensive Experience in Diagnostics and Financial Strategy

3 days ago - GlobeNewsWire

Mainz Biomed Appoints Dr. Douglas Rex to its Medical Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

1 week ago - GlobeNewsWire

Mainz Biomed Reports First Half 2022 Financial Results

BERKELEY, Calif. and MAINZ, Germany, Sept. 07, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

3 weeks ago - GlobeNewsWire

Mainz Biomed to Present at the H.C. Wainwright Annual Global Investment Conference

BERKELEY, Calif. and MAINZ, Germany, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

1 month ago - GlobeNewsWire

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

BERKELEY, Calif. and MAINZ, Germany, Aug. 23, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

1 month ago - GlobeNewsWire

Mainz Biomed and Dante Genomics Announce Full Commercial Availability of ColoAlert in Italy and the United Arab Emirates

– ColoAlert to be marketed through Dante's extensive database and sold via its region-specific, ecommerce websites – – ColoAlert to be marketed through Dante's extensive database and sold via its region...

1 month ago - GlobeNewsWire

Mainz Biomed Appoints Former QIAGEN Executive Dr. Frank Krieg-Schneider as Vice President of Development

Dr. Frank Krieg-Schneider to lead development across Mainz Biomed's portfolio of advanced cancer detection products including its flagship product ColoAlert and future diagnostic tests Dr. Frank Krieg-S...

1 month ago - GlobeNewsWire

Mainz Biomed Appoints Dr. Timothy Wang to Newly Formed Medical Advisory Board

BERKELEY, Calif. and MAINZ, Germany, July 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

2 months ago - GlobeNewsWire

Mainz Biomed Today to Provide Corporate Update for First Half of 2022

Company to Host Webcast Today - July 12th - at 4.00pm ET Company to Host Webcast Today - July 12th - at 4.00pm ET

2 months ago - GlobeNewsWire

Mainz Biomed Provides Corporate Update for First Half of 2022

Company to Host Webcast on July 12 at 4.00pm ET Company to Host Webcast on July 12 at 4.00pm ET

2 months ago - GlobeNewsWire

Mainz Biomed Enrolls First Patient in ColoFuture Study Evaluating Integration of Novel mRNA Biomarkers into ColoAlert

BERKELEY, Calif. and MAINZ, Germany, June 28, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the earl...

3 months ago - GlobeNewsWire

Mainz Biomed Appoints Vice President of Clinical Affairs to Lead US Clinical Studies in Support of FDA Submission

Jane Edwards, CCRA, RAC brings over 20 years of senior experience developing optimal product and clinical trial strategies in diagnostics and medical devices

3 months ago - GlobeNewsWire

Mainz Biomed Successfully Completes Conformity Assessment to IVDR Achieving New Level of EU Regulatory Compliance

New and stringent EU regulation on in vitro diagnostic medical devices sets a higher standard of quality and safety for in vitro diagnostic (IVD) products and manufacturer process New and stringent EU r...

4 months ago - GlobeNewsWire

Mainz Biomed & Dante Labs Announce Partnership for the Commercialization of ColoAlert in Europe and the United Arab E...

BERKELEY, Calif. and MAINZ, Germany and NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz” or the “Company”), a molecular genetics diagnostic company specializing in the...

4 months ago - GlobeNewsWire

Mainz Biomed to Participate in H.C. Wainwright Global Investment Conference and Equity Forum German Spring Conference

BERKELEY, Calif. and MAINZ, Germany, May 17, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...

4 months ago - GlobeNewsWire

Mainz Biomed to Host Key Opinion Leader Event at DDW 2022

BERKELEY, Calif. and MAINZ, Germany, May 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...

4 months ago - GlobeNewsWire

Mainz Biomed Provides Product Development Update on PancAlert

BERKELEY, Calif. and MAINZ, Germany, May 05, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early...

4 months ago - GlobeNewsWire

Mainz Biomed Appoints Darin Leigh as Chief Commercial Officer

Former Abbott and Luminex executive with over 30 years of In Vitro Diagnostic (IVD) and life science research experience appointed to execute the international commercialization of ColoAlert and drive t...

5 months ago - GlobeNewsWire

Mainz Biomed Announces First Quarter 2022 Results

BERKELEY, Calif. and MAINZ, Germany, April 12, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

5 months ago - GlobeNewsWire

Mainz Biomed Completes Successful Pre-Submission Process with the U.S FDA for ColoAlert's Pivotal Clinical Trial

BERKELEY, Calif. and MAINZ, Germany, March 31, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

6 months ago - GlobeNewsWire

Mainz Biomed to Ring Nasdaq Stock Market Closing Bell

BERKELEY, Calif. and MAINZ, Germany, March 21, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

6 months ago - GlobeNewsWire

Mainz Biomed Appoints Key Clinical Trial Partners for ColoFuture Study

- ColoFuture on track to complete enrollment in 2H 2022 -

6 months ago - GlobeNewsWire

Mainz Biomed Announces Year End 2021 Results

BERKELEY, Calif. and MAINZ, Germany, March 09, 2022 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the ear...

6 months ago - GlobeNewsWire

Mainz Biomed and Partners Join International Awareness Campaign for Colorectal Cancer Awareness Month

Mainz Biomed joins a collective of physicians, healthcare professionals, laboratories and healthcare organizations as part of the international Colorectal Cancer Awareness Month initiative

7 months ago - GlobeNewsWire

Mainz Biomed Provides U.S. Regulatory Review Update for ColoAlert

Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug Administration Pivotal Clinical Trial Pre-Submission Accepted for Review by the U.S. Food & Drug Administration

7 months ago - GlobeNewsWire